Biophytis publishes its interim financial report for the first half of 2022 and its adjusted financial results as of 31 December 2021 Biophytis publishes its interim financial report for the first half of 2022 and its adjusted financial results as of 31 December 2021. Fullscreen Mode
Judgment of the Paris Court of Appeal of 17 January 2023 in the case between Biophytis and Negma Group Ltd The Paris Court of appeal confirms the judgement of the Paris Conmmercial Court of 16th of March 2021 Fullscreen Mode
Biophytis announces its participation in two major investor conferences in January, in the United States and in France: the JP Morgan Healthcare Conference and the Invest Securities Biomed Event.
Following the positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in the treatment of pneumonia in COVID-19 patients at risk of respiratory failure, Biophytis management is inviting all of Biophytis’ stakeholders to an online event with KOL.
Biophytis reports positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in COVID-19 Biophytis released the full results from its phase 2-3 COVA clinical study evaluating Sarconeos (BIO101) in the treatment of COVID-19-related respiratory failure. A reduction in the risk of early death or respiratory failure at day 28 of 45% in the Intent-To-Treat (ITT) population and 53% in the Per Protocol (PP) population A reduction in the risk of death at day 90 of 43% in the ITT population and 70% in the PP population The start of regulatory development of
Biophytis publishes its key financial figures as at 30 June 2022, announces a restatement of the financial statements published as of December 31st, 2021 and provides an update on the operational milestones Fullscreen Mode
Biophytis announces receipt of Nasdaq Notice Biophytis announced that it has received written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) dated October 20, 2022, indicationg that, based upon a closing bid price of less than $1.00 per share for the Company’s American Depositary Shares (“ADSs”) for the prior 30 consecutive business deay period, the Company no longer satisfies Nasdaq Listing Rule 5550(a)(2). The Notification Letter has no immediate effect on the listing of the ADSs, and they will continue to trade on The Nasdaq Global Select Market under the symbol “BPTS”. Pursuant to Nasdaq Listing Rule
Biophytis participates in H.C. Wainwright 24th Annual Global Investment Conference Biophytis made a presentation to investors on the 12th of September in New York, on the occasion of the 24th Global Investment Conference organised by the HC Wainwright bank, which is being held from 12 to 14 September 2022 in New York. During this oral presentation, Stanislas Veillet, CEO of Biophytis, gave an update on the company’s clinical results, presented the first results of the phase 2-3 COVA study in COVID-19-related respiratory failure and detailed the company’s next key steps. Stanislas Veillet, CEO of Biophytis, said: “I am very happy
Biophytis announces that on the 8th of September 2022 the Paris Court of Appeal rendered a decision in the case between Biophytis and Negma Group Ltd.
Biophytis released top-line results from its phase 2-3 COVA clinical study evaluating Sarconeos (BIO101) in the treatment of COVID-19-related respiratory failure